Company Information

  

Address: 120 BROADWAY, 32ND FLOOR  
City: NEW YORK 
State: NY 
Zip Code: 10271 
Telephone: 212 238-3128 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Benitec Biopharma Limited was incorporated under the laws of Australia in 1995 and has been listed on the Australian Securities Exchange, or ASX, since 1997. Since we were incorporated in Australia in 1995, we have devoted the majority of our resources to development efforts relating to ddRNAi. While we have established some licensing arrangements, we do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations primarily from private placements of ordinary shares, including A$31.5 million of gross proceeds raised in February 2014, and our U.S. initial public offering in August 2015, the gross proceeds of which equaled US$13.8 million. We have also been awarded research and development grants from the Australian federal government, totaling A$2.3 million in fiscal 2015 and A$3.6 million in fiscal 2016.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
There's no share overview data.

Key Financial Ratios and Statistics

FYE: 06/30

Profitability 2015 Leverage 2015
Net Inc/Comm Equity-0.09Total Liab/Total Assets0.06
Net Inc/Total Assets-0.45Total Liab/Inv Cap0.07
Net Inc/Inv Cap-0.48Total Liab/Comm Equity0.01
Pretax Inc/Net Sales-2.90Interest Coverage RatioNA
Net Inc/Net Sales-2.90Curr Debt/EquityNA
Cash Flow/Net Sales-2.44LTD/EquityNA
SG&A/NetSales1.76Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover1.12Quick Ratio15.26
Inventory TurnoverNACurrent Ratio15.26
Inventory Day SalesNANet Rec/Curr Assets0.13
Net Sales/Work Cap0.17Inv/Curr AssetsNA
Net Sales/PP&E8.72  

Income Statement (Millions)

  6/30/2015 12/31/2014 6/30/2014 6/30/2013
Total Revenues(Net Sales) 3.05 0.52 1.30 1.34
Cost of Goods Sold 0.89 0.44 0.73 0.40
Selling & Admin Exps 5.37 2.70 3.80 0.80
Operating Income -8.02 -4.45 -6.97 -2.44
Interest Exp NA NA NA NA
Pretax Income -8.85 -4.13 -7.07 -3.19
Other Income -0.82 0.32 -0.11 1.40
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -8.85 -4.13 -6.64 -3.19

Balance Sheet (Millions)

Assets 6/30/2015 12/31/2014 6/30/2014 6/30/2013
Cash & Short Term Investments 16.75 21.95 29.60 1.45
Receivables - Total 2.52 0.06 2.92 0.10
Inventories - Total NA NA NA NA
Total Current Assets 19.26 24.48 32.51 1.58
Net Property, Plant & Equipment 0.35 0.34 0.05 0.03
Total Assets 19.62 24.83 32.56 1.60
Liabilities        
Accounts Payable 1.11 0.44 0.74 0.93
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 1.26 0.59 0.90 1.02
Long-Term Debt NA NA NA NA
Total Liabilities 1.26 0.59 0.90 1.02
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 99.64 106.02 121.93 82.02
Retained Earnings -82.85 -82.92 -90.88 -81.69
Treasury Stock NA NA NA NA
Total Stockholders' Equity 18.35 24.24 31.66 0.59
Total Liabilities and Stockholders' Equity 19.62 24.83 32.56 1.60

Cash Flow Summary (Millions)

Categories 6/30/2015 12/31/2014 6/30/2014 6/30/2013
Net Cash Provided by Operating Activities -7.45 -3.92 -8.75 -2.50
Net Cash Provided by Investing Activities -0.39 -0.32 -0.03 0.12
Net Cash Provided by Financing Activities 0.04 0.21 36.88 0.99

Annual Summary Data (Millions)

Year Sales Net Income EPS
06/20141.30-6.64--
06/20153.05-8.85--
Growth Rates135.39----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/173140--




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.